All In Biotech

Drug Trial Radar · NCT06967857

Clinical Trial to Investigate the Safety and Efficacy of Two Dexamfetamine Sulfate Formulations in Adults With ADHD and Moderate to Severe Depression

Randomized, Placebo-controlled Clinical Trial to Investigate the Safety and Efficacy of Two Dexamfetamine Sulfate Formulations in Adults With ADHD and Moderate to Severe Depression (DEXAD)

Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

105

Planned (sponsor's estimate)

Start

May 15, 2025

Primary completion

Mar 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Prof. Dr. Frank BehrensAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The indication of attention-deficit/hyperactivity disorder (ADHD) to be examined often occurs with other psychiatric disorders, and the majority of adults with ADHD have at least one psychiatric comorbidity in their lives. Depression is one of the most common comorbidities in patients with ADHD. The prevalence of comorbid depression in adults with ADHD is estimated to be as high as 50%. There is evidence that stimulants such as dexamfetamine and methylphenidate lead to an improvement in sustained focused attention, working memory, and a variety of cognitive processes in the prefrontal cortex (PFC). In combination with the pharmacological effects of stimulants, such as the inhibition of monoamine oxidase, the increase in the concentration of noradrenaline in the PFC and dopamine in the striatum, dexamfetamine and methylphenidate could improve the treatment of depression in patients with major depressive disorder and comorbid ADHD. This clinical trial will evaluate the safety and efficacy of DEX in two different formulations compared to placebo in adults with ADHD and moderate to severe depression. To ensure double blinding of the treatment, placebo will be administered in the form of tablets and capsules.

Conditions

  • Attention-Deficit/Hyperactivity Disorder (ADHD)
  • Depression - Major Depressive Disorder

Interventions

  • DEX IR tabletsDrug

    tablet twice daily

  • DEX XLDrug

    capsule once daily

  • PlaceboDrug

    Placebo to either capsule or tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AE) in the active treatment groups compared to the placebo until V6Time frame: from enrollment to the end of study at week 17

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Charité - Universitätsmedizin Berlin Klinik für Psychiatrie und Psychotherapie, Campus Benjamin Franklin

    Berlin, Germany · Recruiting

  • Universitätsklinikum Bonn AöR, Klinik und Poliklinik für Psychiatrie und Psychotherapie

    Bonn, Germany · Recruiting

  • Department of Psychiatry, Psychosomatics and Psychotherapy University Hospital Frankfurt am Main - Goethe University

    Frankfurt, Germany · Recruiting

  • University Leipzig, Department of Psychiatry and Psychotherapy

    Leipzig, Germany · Recruiting

  • LMU Klinikum München Klinik für Psychiatrie und Psychotherapie

    München, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.